Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
Abstract Ankylosing spondylitis is a chronic, progressive disease, and its treatment is relevant to the gut microbiota. Anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease. However, little is known about the effect of...
Main Authors: | Bin Liu, Lianjun Yang, Zhifei Cui, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Zhihai Su, Min Wang, Weicong Zhang, Jinshi Liu, Tingxuan Wang, Qingchu Li, Hai Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | MicrobiologyOpen |
Subjects: | |
Online Access: | https://doi.org/10.1002/mbo3.927 |
Similar Items
-
Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
by: Lianjun Yang, et al.
Published: (2019-03-01) -
Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis
by: Hsu-Wen Tseng, et al.
Published: (2017-05-01) -
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
by: F.M. Perrotta, et al.
Published: (2014-11-01) -
Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
by: Bahar Say, et al.
Published: (2019-09-01) -
EFFICACY DIFFERENCES BETWEEN CLASSICAL AND BIOLOGICAL TREATMENT IN ANKYLOSING SPONDYLITIS
by: Claudiu Popescu, et al.
Published: (2016-09-01)